Evidence map›Paper›PMID 29617363›Full record

ArticlePloS one2018

Pre-exposure to 50 Hz-electromagnetic fields enhanced the antiproliferative efficacy of 5-fluorouracil in breast cancer MCF-7 cells.

Qi Han, Rui Chen, Fangjie Wang, Sha Chen, Xiongshan Sun, Xiao Guan, Yao Yang, Bingjie Peng, Xiaodong Pan, Jinfang Li and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Qi HanGeneral Hospital of Tibet Area Military Command, Lhasa, China.
Rui ChenTibetan Traditional Medical College, Lhasa, China.
Fangjie WangInstitute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing, China.
Sha ChenDepartment of Clinical Biochemistry, Faculty of Medical Laboratory Science, Southwest Hospital, Third Military Medical University, Chongqing, China.
Xiongshan SunInstitute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing, China.
Xiao GuanInstitute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing, China.
Yao YangInstitute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing, China.
Bingjie PengDepartment of Clinical Biochemistry, Faculty of Medical Laboratory Science, Southwest Hospital, Third Military Medical University, Chongqing, China.
Xiaodong PanInstitute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing, China.
Jinfang LiDepartment of Clinical Biochemistry, Faculty of Medical Laboratory Science, Southwest Hospital, Third Military Medical University, Chongqing, China.
Weijing YiDepartment of Clinical Biochemistry, Faculty of Medical Laboratory Science, Southwest Hospital, Third Military Medical University, Chongqing, China.
Peng LiUrology, 201th Hospital of People's Liberation Army, Liaoyang, China.
Hongwei ZhangGeneral Hospital of Tibet Area Military Command, Lhasa, China.
Dongfang FengGeneral Hospital of Tibet Area Military Command, Lhasa, China.
An ChenDepartment of Clinical Biochemistry, Faculty of Medical Laboratory Science, Southwest Hospital, Third Military Medical University, Chongqing, China.
Xiaohui LiInstitute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing, China.
Shuhui LiDepartment of Clinical Biochemistry, Faculty of Medical Laboratory Science, Southwest Hospital, Third Military Medical University, Chongqing, China.ORCID 0000-0002-1697-5334
Zuoming YinGeneral Hospital of Tibet Area Military Command, Lhasa, China.
Army Medical University · CNTibet Autonomous Region People's Hospital · CNTibetan Traditional Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to 5-fluorouracil (5-FU) and its induced immune suppression have prevented its extensive application in the clinical treatment of breast cancer. In this study, the combined effect of 50 Hz-EMFs and 5-FU in the treatment of breast cancer was explored. MCF-7 and MCF10A cells were pre-exposed to 50 Hz-EMFs for 0, 2, 4, 8 and 12 h and then treated with different concentrations of 5-FU for 24 h; cell viability was analyzed by MTT assay and flow cytometry. After pre-exposure to 50 Hz-EMFs for 12 h, apoptosis and cell cycle distribution in MCF-7 and MCF10A cells were detected via flow cytometry and DNA synthesis was measured by EdU incorporation assay. Apoptosis-related and cell cycle-related gene and protein expression levels were monitored by qPCR and western blotting. Pre-exposure to 50 Hz-EMFs for 12 h enhanced the antiproliferative effect of 5-FU in breast cancer cell line MCF-7 in a dose-dependent manner but not in normal human breast epithelial cell line MCF10A. Exposure to 50 Hz-EMFs had no effect on apoptosis and P53 expression of MCF-7 and MCF10A cells, whereas it promoted DNA synthesis, induced entry of MCF-7 cells into the S phase of cell cycle, and upregulated the expression levels of cell cycle-related proteins Cyclin D1 and Cyclin E. Considering the pharmacological mechanisms of 5-FU in specifically disrupting DNA synthesis, this enhanced inhibitory effect might have resulted from the specific sensitivity of MCF7 cells in active S phase to 5-FU. Our findings demonstrate the enhanced cytotoxic activity of 5-FU on MCF7 cells through promoting entry into the S phase of the cell cycle via exposure to 50 Hz-EMFs, which provides a novel method of cancer treatment based on the combinatorial use of 50 Hz-EMFs and chemotherapy.

Indexed as

Magnetic Field TherapyAntimetabolites, AntineoplasticApoptosisBreast NeoplasmsCell CycleCell LineCell ProliferationCell SurvivalCombined Modality TherapyElectromagnetic FieldsFemaleFluorouracilHumansMCF-7 CellsAntimetabolites, AntineoplasticFluorouracil

Identifiers

PMID29617363
PMCPMC5884488
OpenAlexW2796418531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.